U.S. Antiviral Drugs Market (2025 - 2030)

U.S. Antiviral Drugs Market Summary

The U.S. antiviral drugs market size was estimated at USD 26.41 billion in 2024 and is projected to reach USD 23.61 billion by 2030, growing at a CAGR of -1% from 2025 to 2030. This decline is largely due to the waning demand for COVID-19-specific antivirals, as the number of severe COVID-19 cases and related hospitalizations has dropped significantly in 2025.

Treatments for HIV, hepatitis B and C, herpes, and influenza primarily drive the U.S. market for antiviral drugs. The CDC estimates that about 1.2 billion people in the U.S. are living with HIV, 2.4 billion with hepatitis C, and 850,000 with hepatitis B. The CDC reports that acute respiratory illnesses, including influenza, COVID-19, and RSV, remain at very low levels in the U.S. as of mid-2025, reducing the immediate demand for antiviral medications. This low incidence, combined with the growing use of complementary health approaches for symptom relief and immune support, has moderated the growth of the antiviral drugs market.

Despite these advancements, the high cost of antiviral treatments remains a significant challenge for many patients and healthcare systems in the U.S. For instance, the hepatitis C drug Sovaldi costs approximately USD 1,000 per pill, resulting in a total treatment cost of around USD 84,000 for a 12-week course . Similarly, Olysio’s monthly treatment cost is estimated at USD 23,600, with treatment durations extending up to 48 weeks.

Regulatory oversight by the U.S. Food and Drug Administration (FDA) plays an essential role in shaping the antiviral drugs industry. The FDA’s rigorous approval process ensures safety and efficacy, with recent approvals emphasizing combination therapies and pediatric indications. In June 2025, the FDA approved the expanded use of Mavyret for acute hepatitis C in children aged 3 and above.

Type Insights

The branded antiviral drugs segment held the largest share of 61.7% in 2024. This growth is driven by the widespread use of patented medications with proven efficacy and safety profiles. Branded antivirals are widely prescribed due to their clinical validation and regulatory approvals by the FDA. The dominance of branded drugs is supported by extensive clinical trials and strong patent protections that incentivize pharmaceutical companies to invest in novel therapies.

The generic antiviral drugs segment is expected to grow at a CAGR of 1.7% over the forecast period. It is driven by growing demand for affordable treatment options as patents on several key branded antivirals, including efavirenz and tenofovir, have expired. This has enabled numerous generic pharmaceutical manufacturers, such as Teva Pharmaceuticals, Mylan, and Sandoz, to enter the market, increasing competition and improving drug affordability.

Drug Class Insights

The reverse transcriptase inhibitors (RTIs) segment dominated the market in 2024, primarily due to their critical role in the management of HIV infection. RTIs target the reverse transcriptase enzyme, essential for HIV replication, and form the backbone of most antiretroviral therapy (ART) regimens recommended by the U.S.

The DNA polymerase inhibitors segment is expected to grow at the fastest CAGR over the forecast period. This growth is driven largely by their expanding use in treating chronic hepatitis B and herpes simplex virus infections.

Application Insights

The HIV segment held the largest market share and is expected to grow rapidly during the forecast period. This growth reflects the need for effective antiretroviral therapy (ART) to manage this chronic infection. ART drugs work by targeting various stages of the HIV lifecycle to suppress viral replication, reduce viral load, and delay disease progression. Recent trends emphasize the development of single-tablet regimens (STRs) that combine multiple antiviral agents into one pill , enhancing patient adherence and treatment convenience.

The herpes segment is expected to experience the fastest growth over the forecast period. This is driven by the high prevalence of herpes simplex virus (HSV) infections and increased awareness leading to more diagnoses and treatment. Antiviral drugs are widely used to control HSV and varicella-zoster virus (VZV) infections. However, challenges remain due to the potential development of drug-resistant HSV strains, especially in patients requiring long-term suppressive therapy. This has spurred ongoing research into novel antiviral agents and treatment strategies to address resistance and improve patient outcomes.

Distribution Channel Insights

The hospital pharmacy held the largest market share in 2024. This growth is driven by the high prevalence of viral infections requiring inpatient care and acute treatment. The aging population and increasing hospitalizations for conditions such as HIV-related complications, hepatitis flare-ups, and severe influenza contribute significantly to this dominance.

The online pharmacy segment is expected to grow over the forecast years. The rapid expansion of telehealth and digital health services drives the growth. Online pharmacies provide convenient access to antiviral medications for chronic infections as well as acute illnesses, with home delivery and streamlined prescription management.

Key U.S. Antiviral Drugs Company Insights

Some of the key players operating in the market include F. Hoffmann-La Roche Ltd, GSK plc., AbbVie, Inc., Merck & Co. Inc., and others.

• GSK plc. (GlaxoSmithKline) is a leading healthcare company active in the U.S. antiviral drugs market, offering treatments for HIV, influenza, and other viral infections. GSK develops and markets antiretroviral therapies, including single-tablet regimens, and invests in vaccine research to prevent viral diseases. The company prioritizes innovation to enhance viral infection management and patient adherence.

• AbbVie, Inc. is a global biopharmaceutical company focused on developing and delivering innovative antiviral therapies, particularly for HIV and hepatitis C.

U.S. Antiviral Drugs Market